Using Real-World Data to Understand Patient Journeys in Dermatology
Listen to OM1’s podcast episode on the Medical Affairs Professional Society (MAPS) “Elevate” podcast series. Dr. Stefan Weiss is discussing ways to transform the way we conduct safety studies — relying more on EMR patient data overlain with technology to create a more accurate and equitable view of post-market safety. Moving away from cumbersome and[…]
› LISTEN TO THE PODCASTPOSTERS
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
DEC 2, 2022
View our poster on Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients. Click to view!
Effect of Patient Reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice
DEC 2, 2022
View our poster on Effect of Patient Reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice. Click to view more!
EVENTS
SCOPE Summit for Clinical Ops Executives
JAN 27, 2023
When: February, 6-9, 2023 Where: Rosen Shingle Creek in Orlando, FL Booth Location: Find our experts at booth #100 Don’t miss out on our presentation on Getting the Most out of Structured and Unstructured Real-World Data for Evidence Generation. Presenter: Jess Paulus, VP of Research, OM1 Date: Wednesday, February 8 Time: 12:50 PM – 1:20[…]
Visit us at the Crohn’s & Colitis Congress
JAN 11, 2023
When: January 19th-21st, 2023 Where: The Gaylord Rockies Convention Center, Denver, CO Booth Location: Find our experts in booth #619 Leveraging our extensive clinical networks and artificial intelligence (AI) platform, OM1 offers industry-leading enriched healthcare datasets, research analytics, data modeling, decision support, and retrospective and prospective clinical studies. With a focus on high-quality data and[…]
EBOOKS
Findings from OM1 Real-World Data: Rheumatoid Arthritis, Heart Failure, Depression, and Schizophrenia
JAN 11, 2023
At OM1, we use both RWD to create digital data networks and AI powered tools to answer research questions and improve patient outcomes. In this E-Book you will find a sampling of posters detailing studies that address questions in: Rheumatoid Arthritis Heart Failure Depression Schizophrenia Systemic Lupus Erythematosus Real-World Data Methodologies And more! Download >>[…]
Analyses & Insights from OM1 Heart Failure Datasets
JAN 11, 2023
At OM1, we use both RWD to create digital data networks and AI powered tools to answer research questions and improve patient outcomes. In this E-Book you will find a sampling of posters and case studies that address questions in Heart Failure with solutions and considerations in AI and predictive modeling. Download >> *Due to[…]
NEWS & ARTICLES
Kazuki Yoshida, MD, MPH, ScD: Methotrexate Access in the Post-Roe v Wade Era
DEC 2, 2022
Published: December 1, 2022 Rheumatology Network Read the Full Article >> In the wake of the Supreme Court’s decision to overturn Roe v Wade, results of a recent study indicated that more than half of female patients treated with methotrexate, a commonly-prescribed drug used to manage rheumatic diseases, lived in states with abortion restrictions or[…]
Validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis
DEC 2, 2022
Published: June 22, 2022 Sage Journals Read the Full Article >> Background: Disability assessment using the Expanded Disability Status Scale (EDSS) is important to inform treatment decisions and monitor the progression of multiple sclerosis. Yet, EDSS scores are documented infrequently in electronic medical records. Objective: To validate a machine learning model to estimate EDSS scores[…]
WHITE PAPERS
From Big Data to Measurable Outcomes: OBC
JUL 6, 2017
A heightened focus on value is driving efforts across health care to improve outcomes and reduce costs. For pharmaceutical companies, this focus translates into a shift away from traditional payment models to more outcomes-based, risk sharing agreements. In many ways, these agreements present the opportunity to better align interests across health care’s stakeholders. However, they[…]
Improving Performance under Bundled Care
NOV 5, 2016
The field of medicine is changing rapidly due to two major disruptions – the application of artificial intelligence, such as machine and deep learning and the shift from fee-for-service to value-based payment models. These innovations, which are occurring simultaneously, are fundamentally altering how data are used and how care is provided. To survive in this[…]
WEBINARS
Getting the Most out of Structured and Unstructured Real-World Data for Evidence Generation
JAN 20, 2023
Tue, Feb 21, 2023 2:00 PM – 3:00 PM EST Presenters: Jessica Paulus, ScD, VP of Research, OM1 and Anna Swenson, Senior Epidemiologist, OM1 Register >> Structured data, what’s found in an electronic medical record or claims, and unstructured data, what’s found in clinician notes, provide valuable insights into treatment effectiveness and safety, gaps in[…]
Using AI to Accelerate Diagnosis and Treatment
DEC 5, 2022
In this episode of the Medical Affairs Professional Society (MAPS) podcast ELEVATE, Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1 discusses how Artificial Intelligence can accelerate diagnosis and treatment. Listen to the Full Episode >>